The VRBPAC “plays a critical role in advising FDA regarding the regulatory approval of all vaccines for use in the U.S., including but limited to all COVID-19 vaccines, and I am honored to be asked to serve,” said Dr. Reingold.
The committee will be holding meetings throughout the summer “in anticipation of complete submissions of emergency use authorization (EUA) requests in the coming months that have been publicly announced by COVID-19 vaccine manufacturers,” according to a press release.
“As we continue to address the ongoing COVID-19 pandemic, there are a number of anticipated submissions and scientific questions that will benefit from discussion with our advisory committee members,” said Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research. “The agency is committed to a thorough and transparent process that considers the input of our independent advisors and provides insight into our review of the COVID-19 vaccines. We intend to move quickly with any authorizations that are appropriate once our work is completed.”